Functional somatic syndrome

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Retrieved on: 
Tuesday, November 29, 2022
Health, FDA, COVID-19, General Health, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Real estate, BHC, Diagnosis, Metal, Attention, Agriculture, Conditional sentence, Long COVID, Center of excellence, Pain, Indian stock exchange, Therapy, Valaciclovir, Fibromyalgia, Sleep, Fatigue, Perpetual Real Estate Services, Inc. v. Michaelson Properties, Inc., Financial services, FM, Anxiety, Consumer, Planet, Publishing, News, Functional somatic syndrome, Short bowel syndrome, Celecoxib, Famciclovir, PASC, Chronic fatigue syndrome, FDA, Simplex, Pharmaceutical industry, Health care, Mining

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Key Points: 
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Planet MicroCap is a global multimedia and publishing financial news investor portal specifically focused on covering the MicroCap market by providing news, insights, education tools and expert commentary.
  • The Planet MicroCap Showcase will take place virtually, featuring 50+ companies, buy-side and sell-side analysts, wealth managers, institutional investors, family offices, hedge fund managers, retail investors and others.
  • Sectors Participating: Agriculture, Biopharma, Consumer, Energy, Financial Services, Healthcare, Industrials, Materials, Metals and Mining, Real Estate, Services, and Technology.

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
COVID-19, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, FDA, Center of excellence, Communication, Advertising, Clinical trial, Anxiety, Grammatical mood, Valaciclovir, Simplex, Environment, Fibromyalgia, Functional somatic syndrome, Drug development, Therapy, Database, Short bowel syndrome, Famciclovir, Patient, Conference, Attention, PASC, Doctor of Philosophy, Fatigue, Vaccination, COVID, FM, Research, Depression, Chronic fatigue syndrome, Celecoxib, Sleep, Pain, Conditional sentence, COVID-19, Diagnosis, COVID-19 testing, BHC, Webcast, Pharmaceutical industry, MD

Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.

Key Points: 
  • Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.
  • General and administrative expenses for the third quarter ended September 30, 2022 were $0.9 million, compared to $1.1 million for the third quarter ended September 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on November 14, 2022, at 8:30 a.m.
  • ET to discuss the Companys financial results and provide a corporate update.

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Company, Center of excellence, Fatigue, Simplex, Fibromyalgia, Celecoxib, FDA, Investor, Webcast, Functional somatic syndrome, PASC, Short bowel syndrome, COVID-19, Therapy, Nasdaq, Attention, Famciclovir, Sleep, Conditional sentence, Anxiety, FM, Valaciclovir, Center, Chronic fatigue syndrome, Diagnosis, Pain, BHC, Pharmaceutical industry

Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Virios Therapeutics, Inc. Announces Closing of Public Offering

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Celecoxib, Conditional sentence, ThinkEquity, COVID-19, Short bowel syndrome, State Street, Sale, S-3, U.S. Securities and Exchange Commission, Company, Fibromyalgia, Functional somatic syndrome, Therapy, Valaciclovir, Forward-looking statement, Famciclovir, Attention, Chronic fatigue syndrome, Pain, SEC filing, Annual report, Nasdaq, Anxiety, Private Securities Litigation Reform Act, Telephone, Sleep, Form, Security (finance), Prospectus, SEC, Simplex, Fatigue, FM, Vaccine

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.
  • The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.
  • ThinkEquity acted as sole book-running manager for the offering.
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SECs website at www.sec.gov .

Virios Therapeutics, Inc. Announces Pricing of Public Offering

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Celecoxib, Conditional sentence, ThinkEquity, COVID-19, Short bowel syndrome, State Street, Sale, S-3, U.S. Securities and Exchange Commission, Company, Fibromyalgia, Functional somatic syndrome, Therapy, Valaciclovir, Forward-looking statement, Famciclovir, Attention, Chronic fatigue syndrome, Pain, SEC filing, Annual report, Nasdaq, Anxiety, Private Securities Litigation Reform Act, Telephone, Sleep, Form, Security (finance), Prospectus, SEC, Simplex, Fatigue, FM, Vaccine

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.
  • The offering is expected to close on September 22, 2022, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.
  • ThinkEquity is acting as sole book-running manager for the offering.

Virios Therapeutics, Inc. Announces Proposed Public Offering

Retrieved on: 
Monday, September 19, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Celecoxib, Conditional sentence, ThinkEquity, COVID-19, Short bowel syndrome, State Street, Sale, S-3, U.S. Securities and Exchange Commission, Company, Fibromyalgia, Functional somatic syndrome, Therapy, Valaciclovir, Forward-looking statement, Famciclovir, Attention, Chronic fatigue syndrome, Pain, SEC filing, Annual report, Nasdaq, Anxiety, Private Securities Litigation Reform Act, Telephone, Sleep, Form, Security (finance), Prospectus, SEC, Simplex, Fatigue, FM, Life insurance, Vaccine

The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.

Key Points: 
  • The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.
  • ThinkEquity is acting as sole book-running manager for the offering.
  • The offering will be made only by means of a written prospectus.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Retrieved on: 
Monday, September 19, 2022
Research, Women, FDA, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Celecoxib, BHC, COVID-19, Sleep, Short bowel syndrome, American College, PASC, FDA, Center, ID, Week, Vaccination, Company, Fibromyalgia, Functional somatic syndrome, American College of Rheumatology, Therapy, Valaciclovir, Famciclovir, Patient, Attention, Chronic fatigue syndrome, CEO, Pain, Female, Numerical, Nasdaq, Omicron, Anxiety, Diagnosis, Center of excellence, Simplex, Fatigue, FM, Conditional sentence, Pharmaceutical industry, Medical device, Delta

The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.

Key Points: 
  • The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.
  • Virios Therapeutics will host a conference call and live webcast to discuss the FORTRESS study results today, Monday, September 19th, at 8:30 a.m. Eastern Time.
  • A live webcast and replay of the call will also be available on the Virios Therapeutics, Inc. website at www.virios.com .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Retrieved on: 
Monday, August 15, 2022
Research, Managed Care, General Health, Pharmaceutical, Mental Health, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, FDA, Health, FDA, Short bowel syndrome, Depression, Valaciclovir, Famciclovir, Simplex, Diagnosis, Sleep, PASC, Pain, Attention, Long COVID, Patient, Celecoxib, Therapy, Fatigue, COVID-19, Company, Center, Center of excellence, Conditional sentence, Myalgia, Safety, FM, Anxiety, Functional somatic syndrome, Fibromyalgia, Nasdaq, Chronic fatigue syndrome, Overalls, BHC, Pharmaceutical industry

The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.

Key Points: 
  • The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.
  • BHC is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of chronic fatigue disorders, FM, post-viral syndromes, and related comorbidities.

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022
Public Policy, Government, Biotechnology, Pharmaceutical, General Health, Health, FDA, Healthcare Reform, Clinical Trials, FDA, Short bowel syndrome, Valaciclovir, Famciclovir, Trial of the century, CEO, Simplex, Standard of care, Diagnosis, PASC, Research, Patient, Celecoxib, Therapy, COVID-19, Company, Center, Center of excellence, Conditional sentence, FM, Doctor of Philosophy, Webcast, Functional somatic syndrome, Fibromyalgia, Nasdaq, Investor, MD, Time, Chronic fatigue syndrome, Conference, BHC, Pharmaceutical industry

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.
  • Research and development expenses for the second quarter ended June 30, 2022 were $2.4 million, compared to $3.2 million for the second quarter ended June 30, 2021.
  • General and administrative expenses for the second quarter ended June 30, 2022 were $1.3 million, compared to $1.1 million for the second quarter ended June 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on August 11, 2022, at 8:30 a.m.

Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

Retrieved on: 
Wednesday, August 10, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Short bowel syndrome, Valaciclovir, Famciclovir, Simplex, Diagnosis, Sleep, PASC, Consumer, Pain, Attention, Complimentary, Celecoxib, Therapy, Fatigue, Company, COVID-19, Center of excellence, Center, Conditional sentence, FM, Real estate, Anxiety, Functional somatic syndrome, Communication services sector reshuffle, Fibromyalgia, Conference, Chronic fatigue syndrome, BHC, Pharmaceutical industry, Finance, Technology, Health care

ET

Key Points: 
  • ET
    The conference is completely complementary to qualified investors.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q3 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors.